













Echo Parameters : All Elective ADHF p
(N ¼ 152) (N ¼ 52)
LVEF(%), mean + SD 55.0 + 10.7 49.9 + 13.8
Mean AV Gradient (mmHg), mean + SD 51.8 + 15.6 49.0 + 16.7
AVA (cm2), mean + SD 0.59 + 0.18 0.65 + 0.16
Procedural details All Elective ADHF p
(N ¼ 152) (N ¼ 52)
TF 82 (53.9) 39(75) 0.01
Percutanous 52(63.4%) 25(64.1%)




Edward Sapien 54(35.5%) 14(26.92%)
Edward Sapien XT 94(61.84%) 35(67.31%)
St Jude Portico valve 3(1.97) 2(3.85)
Medtronic core valve 1(0.66) 1(1.92)
Fleuro time Median (25-75%), mins 12(7.3-18.4) 14.3(9.3-
18.3)
NS
Radiation dose Median (25-75%), Gy 2.6(1.9-3.4) 2.4(1.9-3.4) NS
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Background: Patient’s clinical status and comorbidities plays an important role in
clinical success of transcatheter aortic valve replacement procedures (TAVR). Limited
information is available for the safety and efﬁcacy of urgent TAVR in patients with an
active or recent hospitalization for acute decompensated heart failure (ADHF).
Methods: Clinical, procedural and outcome information was prospectively collected
for all patients undergoing TAVR at St Michael’s hospital between 2009
and 2014.Clinical outcomes were compared for patients with a current or recent
(< 3 month) hospitalization for ADHF(ADHF group)and those without ADHF
(elective group).
Results: A total of 204 patients were included in the analysis. 152 patients comprised
the elective group. 52 patients in the ADHF group (two third with active heart failure
at the time of TAVR). The baseline and procedural characteristics are shown in table
1; both groups had comparable pre-procedural co morbidities as assessed by Society
of Thoracic Surgery (STS-Mortality) & Logistic Euro scores. No difference in MACE,
In-Hospital death (6.58 vs. 7.69%, p¼0.76),Myocardial infarction (0.66 vs. 1.96%,
p¼0.35), Stroke (0.6 vs. 0%, p¼1.0),Vascular complication (7.24 vs. 9.62%, p¼0.56)
& bleeding (9.2vs 15.38%, p¼0.21) was found between the two groups. Total length
of stay (LOS) was longer in ADHF group but post-procedure LOS, Intensive care
stay, discharge disposition as well as other secondary endpoints were comparable in
both groups Table 2. Separate analysis limited to active heart failure patients yielded
similar result.
Conclusions: TAVR beneﬁt is preserved among patients with active or recent hos-
pitalization for ADHF resulting in comparable clinical outcomes to elective patients.
These ﬁndings have important implications for the delivery of care and risk counseling




(N ¼ 52) pN¼204
Age, mean + SD 83.74 (6.51) 83 (7) 85.75
(5.19)
0.02
Female mean + SD 50.98 48.03 59.62 NS












HTN, n(%) 147(86.27) 132(86.84) 42(84.62) NS
Diabetes n(%) 57(27.94) 42(27.63) 15(28.85) NS
Dyslipidemia n(%) 129(63.24) 97(63.82) 32(61.54) NS
CAD n(%) 123(60.29) 91(59.87) 32(61.54) NS
Prior MI 58 (28.43) 37 (24.3) 21(40) 0.02
PCI n (%) 34(16.7) 25(16.45) 9(17.3) NS
PVD n(%) 28(13.73) 19(12.50) 9(17.31) NS
CVA n(%) 47(23.04) 39(25.66) 8(15.38) NS
Pulmonary HTN
(RVSP>50mmhg)n(%)
14(7) 10(6.58) 4(7.69) NS
Dialysis n(%) 8(4) 5(3.29) 3(5.77) NS
Prior CVSx n(%) 66(32) 51(34) 15(29) NS
CABG n(%) 63(31) 48(32) 15(29) NS
Valve Surgery n(%) 11(5) 8(5) 3(6) NS














Anticoagulants 34 33 37 NS








Continued in next column
Contrast volume Median (25-75%), ml 84(58.5-
120)
95(60-120) NS
OUTCOMES All Elective ADHF P value
(N ¼ 152) (N ¼ 52)
In Hospital Death n(%) 14(6.9) 10 (6.58) 4 (7.69) 0.76
MI, n(%) 2(0.98) 1(0.66) 1 (1.96) 0.35
Stroke , n(%) 1(0.5) 1 (0.66) 0 (0) 1
Bleeding n(%) 22(10.8) 14(9.21) 8(15.38) 0.21
Vascular Complications n(%) 16(7.8) 11(7.24) 5(9.62) 0.56
Open Repair n(%) 1(0.5) 1(0.66) 0(0)
Limb Ischemia n(%) 2(0.98) 1(0.66) 1(1.92)
AKI n(%) 21(10.3) 14(9.21) 7(13.46) 0.38
Stage 1 n(%) 12(57.1) 8 (57.1) 4(57.1)
Stage 2 n(%) 6(28.6) 4 (28.6) 2(28.6)
Stage 3 n(%) 3(14.2) 2(14.2) 1(14.2)
Dialysis n(%) 2(0.98) 1 (0.66) 1 (1.92) 0.44
AF/AFL n(%) 10.78 19(12.50) 3(5.77) 0.17
PPM n(%) 3.43 5(3.29) 2(3.85) 1.0
Valve embolization n(%) 2(0.98) 1(0.66) 1(1.92) NS
TAV-in-TAV n(%) 1(0.5) 1(0.66) 0 NS
Temponade n(%) 3(1.47) 2(1.32) 1(1.92) NS
Re-OR n(%) 5(2.45) 4(2.63) 1(1.92) NS
Delerium n(%) 32(15.69) 24(15.79) 8(15.38) 0.94
Wound Infection n(%) 2(0.98) 1(0.66) 1(1.92) NS
Sepsis n(%) 1(0.5) 1(0.66) 0(0) 1
LOS Total n(%) 12.02
(15.06)
6(3-9) 15(8-27) <0.01
LOS Total Post TAVR Median (25-75%), days 6 (3-8) 7(3.5-14) NS
LOS ICU n(%) 2.40 (5.33) 1 1 NS
Disposition 0.47
Home independent 68(55.74) 17(44.74) NS
Home assisted 11(9.02) 6(15.79) NS
Rehab 40(32.79) 14(36.84) NS
Nursing home 3(2.46) 1(2.63)
Post-TVAR Echo parameters:
Mean AV Gradient (mmHg), mean + SD 11.5 + 5.1 10.6 + 7.5 NS
EOA (cm2), mean + SD 1.6 + 0.42 1.7 + 0.44 NS
Greater than mild paravalvular AR 11 (7.2) 5 (9.6) NS
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